Home / Health / Earlier Cancer Doses Linked to Longer Survival
Earlier Cancer Doses Linked to Longer Survival
9 Dec, 2025
Summary
- IV immunotherapy given before 3 p.m. linked to better outcomes.
- Patients had 52% lower risk of progression, 63% lower risk of death.
- Circadian rhythms likely influence treatment effectiveness.
A recent study indicates that the timing of cancer treatment could significantly impact patient survival. For individuals with advanced small cell lung cancer receiving IV immunotherapy, doses administered earlier in the day, specifically before 3 p.m., were associated with markedly improved outcomes.
Researchers tracked nearly 400 patients and found that those treated before 3 p.m. experienced a substantial decrease in cancer progression and mortality. This simple adjustment in infusion schedules holds promise as an inexpensive method to enhance survival rates across various healthcare settings.
The observed effects are thought to be related to the body's natural circadian rhythms, which influence bodily processes, including immune responses. While these findings are promising for immediate clinical application, further research is needed to fully understand and leverage biological rhythms for optimizing cancer therapies.
